Introduction: The treatment of total hip arthroplasty (THA) infections is long and costly. However, the number of studies in the literature analysing the real cost of THA revision in relation to their etiology, including infection, is limited. The aim of this retrospective study was to determine the cost of revision of infected THA and to compare these costs to those of primary THA and revision of non-infected THA. Materials and methods: We performed a retrospective cost analysis for the year 2006 using an identical analytic accounting system in each hospital department (according to internal criteria) based on allotment of direct costs and receipts for each department. From January to December 2006, 424 primary THA, 57 non-infected THA revisions and 40 THA revisions due to infection were performed. The different cost areas of the patient's treatment were identified. This included preoperative medical work-up, medicosurgical management during hospital stay, a second stay in an orthopedic rehabilitation hospital (ORH) and post-hospitalisation antibiotic therapy after revision due to infection, as well as home-based hospitalisation (HH) costs, if this was the selected alternative option. We used the national health insurance fee schedule found in the ''Common classification of medical procedures'' and the ''General nomenclature of professional procedures'' applicable in France since September 1, 2005. Hospital costs included direct costs (hospital overhead costs) and indirect costs, (medical, surgical, technical settings and net general service expenses). The calculation of HH costs and ORH costs were based on the average daily charge of these departments. The cost of primary THA was used as the reference. We then compared our surgical costs with those found for the corresponding comparable hospital stay groups (Groupes homogènes de séjour). Results: The average hospital stay (AHS) was 7.5 ± 1.8 days for primary THA, 8.9 ± 2.2 days for non-infected revisions and 30.6 ± 14.9 days for revisions due to infection. The rate of transfer to a rehabilitation hospital (ORH) was 55% for primary THA, 77% in non infected revision cases and 65% in revisions due to infection. Moreover, 30% of these infected THA were prescribed HH. Non-infected THA revisions cost 1.4 times more than primary THA. THA revisions due to infection cost 3.6 times more than primary THA. Discussion: The economic impact of THA infections is considerable. The extra costs are mainly due to an extended hospital stay and to longer rehabilitation consuming significant substantial human and material resources. Conclusion: The cost of treating infected THA is high. Treatment strategies should therefore be optimised to increase the success rate and minimise total costs. Level of evidence: Level IV. Economic and decision analyses, retrospective study
Introduction
According to the technical agency of information on hospitalisation (Agence technique de l'information sur l'hospitalisation) which centralises national data for the program for the data processing of medical information, 117,400 primary total articular arthroplasties (THA) were performed in 2007 in France and 22,427 hip arthroplasties were revised. Despite improvement in procedures for antibiotic prophylaxy and the fight against nosocomial infections, the risk of infection persists and is generally estimated to be less than 1% in primary THA [1] .
Infected arthroplasties are a source of morbidity and even mortality, if infection is acute (septicemia) in these often elderly patients. The cost of treatment is high for society due to the necessity of repeated interventions and hospitalisations and long term intravenous or oral antibiotic treatment.
The number of cost-analysis studies on primary THA is limited [2, 3] . According to one study by Bozic and Ries [4] , the cost of treatment of an infected hip replacement is approximately 100,000 US dollars per patient, or an annual cost of 100 million US dollars. This figure does not include the economic costs of this disease due to sick leave, or possible disability payments.
The aim of this study was to quantify the cost of management of infected THA at the ''Groupe hospitalier Diaconesses-Croix Saint-Simon'' Hospital and to compare it to the cost of primary THA and the management of nonseptic THA.
Materials and methods
A retrospective cost analysis for the year 2006 was performed in each department of our institution using an analytic accounting system. From January to December 2006, 474 primary THA, 57 aseptic revisions and 40 septic revisions were performed.
We identified the different cost areas by following the patients through the clinical treatment process ( Fig. 1 ). After the surgical indication was decided, a standardised preoperative evaluation was performed. The main difference between the preoperative evaluation of a primary THA and of an aseptic THA revision was the aspiration arthrography [5] of the hip with bacteriological culture analysis of the aspirate culture or liquid from articular lavage. At least, one bone scintigraphy was performed during septic THA revision.
Different costs of medicosurgical treament included:
• medical and non-medical human resource costs, mainly salaries; • medical prescriptions (pharmaceutical products, medical products, medical transportation) and hip prostheses; • general expenses, amortisement costs (medical material and computers) and financial expenses; • net costs of medicotechnical platforms: surgical unit, anesthesia, physiotherapy, radiology, laboratory costs, day hospital services, pharmacy; • net cost of general services: administrative, maintenance, meal and linen services.
An hourly cost was determined for the surgical unit by dividing the cost of orthopedics (aseptic and septic) and anesthesia by the total number of hours that orthopedic surgeons and anesthesiologists spent in the operating room plus the number of hours spent in the surgical recovery room (SRR).
In case of revision of septic THA, intravenous antibiotic therapy was administered for 6 weeks, then orally for another 6 weeks.
The patient was discharged to go home or to an ORH depending on his/her functional condition, degree of independence, and the type of rehabilitation required. For septic THA revisions, the patient was discharged either to an ORH or received home hospital care (HH):
• HH could be proposed before the end of intravenous antibiotic treatment if the clinical and biological course of the disease was favourable, if the patient's functional condition was satisfactory and if they had help at home for daily activities (shopping, meals. . .). In this case, home hospitalisation was monitored by a nurse with a weekly biological work-up, (NFS, blood ion, liver tests, CRP) and sent by fax to the patient's physician. At the end of intravenous antibiotic treatment, an average of 6 weeks of oral antibiotic treatment had begun. The patient also underwent standard biological laboratory tests every 15 days; • patients were transferred to an ORH when their clinical condition required additional medical care and/or they required physiotherapy and rehabilitation. Orthope-
Figure 1
Clinic treatment process followed by patients for primary total hip arthroplasty (THA), aseptic or septic revision.
dic rehabilitation and follow-up included several types of rehabilitation:
• functional rehabilitation (involving corporal mobility),
• social rehabilitation (involving psychological matters),
• professional rehabilitation (involving reintegration into the work force).
Maintaining independence or regaining independence in dependent patients was one of the main goals of a stay in an ORH.
Results

Preoperative evaluation
We applied the rates found in the national health insurance fee schedule of the common classification of medical acts and the general nomenclature of professional acts applicable on September 1, 2005 (Table 1) . 
Medicosurgical costs during hospitalisation
The average hospital stay (AHS) was 7.5 days ± 1.8 (range 3-25 days) for primary THA 8.9 days ± 2.2 (range 5-19 days) for an aseptic revision and 30.6 days ± 14.9 (range 17-83 days) for a septic THA revision.
Figure 2
Duration of hospitalisation in orthopedic rehabilitation hospital after primary total hip arthroplasty (THA) and septic or aseptic revision (with or without home hospitalisation [HH] or day hospital stays).
To evaluate costs, the average duration of the three operations as well as the duration of anesthesia and monitoring in the SRR were: 4 h 02 ± 1 h 02 (range 1 h 30-9 h 50) for primary THA, 5 h 49 ± 1 h 35 (range 2 h 10-9 h 10) for an aseptic revision 5 h 29 ± 1 h 18 (range 3 h 30-8 h 50) for septic THA revision. The number of THA patients admitted to the inten- sive care unit could be broken down as follows: 12/474 (2.5%) ''primary THA'' patients with an average stay in ICU of 1.9 ± 1.8 (range 1-7 days), 7/57 (12.3%) ''aseptic revision'' patients with an AHS of 1.6 ± 1 (range 1-3 days) and 17/40 (42.5%) ''septic revision'' patients with an AHS of 2.1 ± 1.9 (range 1-7 days). The surgical costs of primary THA, aseptic and septic THA revision are summarized in the following tables (Tables 2-4 ).
Home hospitalisation
Thirty percent of our patients who underwent revision of septic THA were prescribed HH. The average daily cost was 218.20 D . The AHS for HH was 22.7 days. The total cost per patient (average daily cost × AHS) was 4953 D . This included all expenses.
Cost of post-home hospitalisation oral antibiotic treatment
The most frequently prescribed antibiotics are shown in Table 5 . The average cost of oral antibiotic treatment was between 171.13 and 214.25 D . The cost of standard biological tests (NFS, ESR, CRP, blood ions, liver tests, PT, ACT) was 63.18 D . The cost of this follow-up was 189.54 D . The average total cost of antibiotic treatment was between 360.67 and 403.79 D .
Stay in a center for orthopedic rehabilitation and follow-up
The patients were admitted to different ORH's. The rate of transfer to ORH's was 55% for primary THA, 77% for revision of aseptic THA and 65% for revision of septic THA.
The minimum stay in an ORH for primary THA was 10 days, 15 days for an aseptic revision, and 30 days for a septic revision. These stays were longer if there was additional treatment required in HH care, day hospital care or for complex surgical operations (associated bone graft, two-stage surgery for septic THA), medical complications (comorbidities) or social problems (dependent or patients in isolated living alone or in isolated areas) (Fig. 2) .
The daily cost of an ORH for a primary THA and an aseptic THA revision was 280 D , while it was 380 D for a septic THA. The difference in the daily cost between the management of aseptic and septic THA can be broken down in the following manner: 8 D for laboratory tests, 27 D for antibiotics and 65 D for healthcare personnel. The total minimum cost of hospitalisation in an ORH (average daily cost × AHS) was 2800 D for primary THA, 4200 D for revision of aseptic THA and 11,400 D for a septic THA revision. Table 6 shows the total costs excluding social expenses. Table 7 provides the figures for the subgroups that underwent one or two stage revision of THA.
Total cost
Revision of aseptic THA cost 1.4 times more than primary THA. Revision of septic THA cost 2.6 times more than aseptic revisions and 3.6 times more than primary THA. Two-stage septic THA revisions cost 1.7 times more than a one-stage revision ( Table 7 ).
Discussion
To our knowledge, this is the first French cost analysis of septic THA revisions. This study helps show that the cost of medicosurgical management in case of infection is considerably higher than the fee allotted for the Related Hospital Stay Group (Groupe homogène de séjour) (GHS) used as a reference in the hospital accounting system. Indeed, since the hospital reform law dated July 31, 1991, public and private medical establishments are financed according to their activities based on data from the program for the data processing of medical information (programme de médicalisation des systèmes d'information). For shortterm treatment hospital stays -in medicine, surgery or obstetrics (MSO) -this analysis is based upon the systematic collection of a small amount of medical and administrative data which makes up a standardised discharge summary (résumé de sortie standardisé) (RSS). The data collected is processed automatically and the RSS are classified into a voluntarily limited number of groups with similar costs and medical diagnoses: called related diagnostic groups (Groupes homogènes de malades) (GHM). A related hospital stay group (GHS) is a fee schedule established for these related diagnostic groups (GHM). The GHS for THA in 2006 are summarized in Table 8 . Unfortunately, the system does not differentiate between revisions for septic and aseptic THA, thus underestimating real costs. Indeed, MSO costs for septic THA revision were 2.9 times more than the allotted 2006 GHS fees. An update of the GHS fees has been available since March 1, 2009 (Table 9 ). However, the MSO cost of a septic revision is still 1.5 times more than the highest updated GHS fee.
The parameter which most significantly affects this difference is the length of stay in MSO and ORH. This extended stay is because of the patient's general condition and the time necessary to adapt antibiotic treatment.
In 2006, the ORH stay was financed by a global sum. A reform is in progress to identify dominant morbidity groups (Groupes de morbidité dominante) (GMD).
Our results for primary THA are similar to those reported by Caton [2] . However, to our knowledge, there are no French studies on septic revisions. Although it is not possi- ble to compare our results directly to those of the American study by Bozic et al. [3] , the relative costs of revision of septic THA compared to an aseptic revision and a primary THA in that study (2.8) (4.8) were comparable to our results. The calculated cost corresponds to one hospital stay. If revision includes two operations, the overall cost per patient includes two hospital stays: first for treatment of septic THA and the second usually for aseptic THA which is why a two stage revision is more costly. A recent prospective study [6, 7] of 100 consecutive cases showed a cure rate of 100% after at least 2 years of follow-up for one-stage THA revisions, which was better than results found for twostage revisions. This difference is most probably due to the decisional tree used, which allowed selection of patients who could be treated with one operation. This suggests that treatment management strategies for septic THA should be adapted to optimise costs while guaranteeing the best results in patients.
Our analytical study did not include ''social'' expenses associated with sick leave, or any social aids which might have been received. Moreover, the other social consequences of a debilitating disease requiring long and difficult treatment may be job loss or changing jobs due to the consequences of the handicap. These effects are difficult to quantify.
Conclusion
The cost of managing a patient being treated for an infected hip arthroplasty is 2.6 times greater than the cost of an aseptic revision and 3.6 times greater than primary THA. These costs are higher than existing approved fee schedules (GHS).
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